ALDH1L2 and colorectal carcinoma: Additional efforts should be made to generate a site-specific antibody against K70 acetylated ALDH1L2, to determine the clinical relevance of ALDH1L2 K70 acetylation in 5-Fu-resistant tumors of CRC patients.